orforglipron vs Semaglutide (Wegovy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Approved in Obesitysmall molecule
Partial signal

NCT05803421 · Phase 3 · completed

ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.

Next expected readout: February 2027 · NCT06672549 (registry estimate)

Reported efficacy

Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)

Result source: NCT05872620

Semaglutide (Wegovy)

Marketed by Novo Nordisk

Approved in Obesitypeptide
Reliable signal

NCT03548935 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.

Next expected readout: December 2026 · NCT05173714 (registry estimate)

Reported efficacy

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)

Result source: NCT03574597

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointorforglipronSemaglutide (Wegovy)
Body weight, % change-7.9% vs -0.6%−7.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
11 other results
  • -8.7% vs -0.6% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • -5.9% vs -0.6% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • -12.3% vs -2% 36 mg · wk 26 · n 56 · Phase 2 · primary NCT05051579
  • -8.6% vs -2% 12 mg · wk 26 · n 44 · Phase 2 · primary NCT05051579
  • -12.6% vs -2% 45 mg · wk 26 · n 57 · Phase 2 · primary NCT05051579
  • -11.2% vs -2% 24 mg · wk 26 · n 51 · Phase 2 · primary NCT05051579
  • -13.5% vs -2.3% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • -9.4% vs -2.3% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • -14.7% vs -2.3% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.5% vs -2.3% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • -9.6% vs -2.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
-19.5% vs -3.8%−15.7 vs placebo7.2 mg · wk 72 · n 950NCT05646706
28 other results
  • -14.2% vs -2.5% 2.4 mg · wk 68 · n 253 · Phase 3 · primary NCT05064735
  • -13.4% vs -1.9% 2.4 mg · wk 68 · n 193 · Phase 3 · primary NCT03811574
  • -14.4% vs -2.7% 2.4 mg · wk 52 · n 129 · Phase 3 · primary NCT05040971
  • -13.9% vs -2.5% 2.4 mg · wk 52 · n 246 · Phase 3 · primary NCT04788511
  • -12.2% vs -2.2% 2.4 mg · wk 44 · n 159 · Phase 3 · primary NCT06041217
  • -12.5% vs -3.6% 2.4 mg · wk 44 · n 238 · Phase 3 · primary NCT04251156
  • -9.9% vs -1.9% 1.7 mg · wk 68 · n 98 · Phase 3 · primary NCT03811574
  • -16.4% vs -2.6% wk 44 · n 100 · Phase 3 · primary NCT04998136
  • -16.4% vs -2.7% wk 44 · n 96 · Phase 3 · primary NCT04998136
  • -16.4% vs -6.4% 2.4 mg · wk 68 · n 117 · Phase 3 · primary NCT04074161
  • -9.4% vs -0.9% wk 104 · n 7474 · Phase 3 · secondary NCT03574597
  • -17.7% vs -5.4% 2.4 mg · wk 68 · n 520 · Phase 3 · secondary NCT03548987
  • -7.8% vs -6% 2.4 mg · wk 8 · n 396 · Phase 3 · secondary NCT03611582
  • -14.8% vs 2.3% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -16.4% vs -1.6% 2.4 mg · wk 68 · n 117 · Phase 3 · secondary NCT04074161
  • -15.8% vs -3.3% 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.9% vs -7.2% 2.4 mg · wk 68 · n 388 · Phase 3 · secondary NCT03552757
  • -19.5% vs -16.4% 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -5.5% vs -3.1% 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · primary NCT04969939
  • -13.8% vs -2.3% 0.4 mg · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -16.3% vs -2.3% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -11.2% vs -2.3% 0.3 mg · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.4% vs -2.3% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.6% vs -2.3% 0.2 mg · wk 52 · n 94 · Phase 2 · primary NCT02453711
  • -8.6% vs -2.3% 0.1 mg · wk 52 · n 96 · Phase 2 · primary NCT02453711
  • -6.0% vs -2.3% 0.05 mg · wk 52 · n 92 · Phase 2 · primary NCT02453711
  • -4.5% vs -0.2% wk 12 · n 43 · Phase 1 · secondary NCT04779697
  • -13.6% vs -7.4% 2.4 mg · wk 52 · n 207 · Phase 4 · secondary NCT05579249
Weight loss of 5% or more58.3% vs 15%+43.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 61.4% vs 15% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • 45.9% vs 15% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • 92.0% vs 24.0% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 89.5% vs 22.9% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 72% vs 24.0% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 74.4% vs 22.9% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 90.4% vs 24.0% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 87.3% vs 22.9% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 89.5% vs 24.0% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 88.8% vs 22.9% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
87% vs 29.2%+57.8 vs placebo2.4 mg · wk 68 · n 253NCT05064735
1 other result
  • 72.5% vs 17.7% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
Weight loss of 10% or more38.3% vs 3.3%+35 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 35.1% vs 3.3% 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • 18.0% vs 3.3% 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • 74.8% vs 8.8% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 71.3% vs 2.3% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 46.5% vs 8.8% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 39.4% vs 2.3% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 69.1% vs 8.8% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 69.9% vs 2.3% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 61.9% vs 8.8% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 56.6% vs 2.3% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
70.4% vs 9.2%+61.2 vs placebo2.4 mg · wk 68 · n 253NCT05064735
9 other results
  • 61.8% vs 8.1% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • 65.9% vs 9.5% 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • 64.6% vs 10.1% 0.4 mg · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 71.9% vs 10.1% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 57.8% vs 10.1% 0.3 mg · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 58.5% vs 10.1% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 56.0% vs 10.1% 0.2 mg · wk 52 · n 94 · Phase 2 · secondary NCT02453711
  • 36.6% vs 10.1% 0.1 mg · wk 52 · n 96 · Phase 2 · secondary NCT02453711
  • 18.9% vs 10.1% 0.05 mg · wk 52 · n 92 · Phase 2 · secondary NCT02453711
Waist circumference, change (cm)-5.7 vs -0.1−5.6 vs placebo36 mg QD · wk 72 · n 60NCT05931380
12 other results
  • -5.9 vs -0.1 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • -3.7 vs -0.1 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • -10.6 vs -4 36 mg · wk 36 · n 52 · Phase 2 · secondary NCT05051579
  • -10.1 vs -3.6 36 mg · wk 26 · n 52 · Phase 2 · secondary NCT05051579
  • -9.6 vs -4 12 mg · wk 36 · n 43 · Phase 2 · secondary NCT05051579
  • -8 vs -3.6 12 mg · wk 26 · n 43 · Phase 2 · secondary NCT05051579
  • -13.6 vs -4 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.2 vs -3.6 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • -11.2 vs -4 24 mg · wk 36 · n 49 · Phase 2 · secondary NCT05051579
  • -8.8 vs -3.6 24 mg · wk 26 · n 49 · Phase 2 · secondary NCT05051579
  • -5.8 n 9 · Phase 1 · secondary NCT06023095
  • -11.7 n 9 · Phase 1 · secondary NCT06023095
-7.5 vs -1−6.5 vs placebowk 104 · n 7373NCT03574597
35 other results
  • -14.1 vs -4.4 2.4 mg weekly · wk 68 · n 1210 · Phase 3 · secondary NCT03548935
  • -6.9 vs 3.2 2.4 mg · wk 68 · n 518 · Phase 3 · secondary NCT03548987
  • -9.7 vs -4.3 2.4 mg · wk 68 · n 387 · Phase 3 · secondary NCT03552757
  • -15.2 vs -6.1 2.4 mg · wk 68 · n 371 · Phase 3 · secondary NCT03611582
  • -18 vs -5.6 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -13.3 vs -5.9 2.4 mg · wk 68 · n 253 · Phase 3 · secondary NCT05064735
  • -12.7 vs -0.5 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -13.6 vs -2 2.4 mg · wk 68 · n 114 · Phase 3 · secondary NCT04074161
  • -11.2 vs -1.8 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -10.2 vs -1.9 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -11.6 vs -2.8 2.4 mg · wk 52 · n 129 · Phase 3 · secondary NCT05040971
  • -12 vs -2.8 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • -14.3 vs -4.5 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.1 vs -2.4 2.4 mg · wk 44 · n 159 · Phase 3 · secondary NCT06041217
  • -11.1 vs -3.8 2.4 mg · wk 44 · n 238 · Phase 3 · secondary NCT04251156
  • -15.2 vs -4.3 2.4 mg · wk 104 · n 143 · Phase 3 · secondary NCT03693430
  • -7.8 vs -1.8 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -7.6 vs -1.9 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -12 vs -3 wk 44 · n 100 · Phase 3 · secondary NCT04998136
  • -4.8 vs -2.7 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · secondary NCT04969939
  • -12.3 vs -3.5 0.4 mg · wk 52 · n 82 · Phase 2 · secondary NCT02453711
  • -14.9 vs -3.5 0.4 mg (Fast Escalation) · wk 52 · n 91 · Phase 2 · secondary NCT02453711
  • -10.9 vs -3.5 0.3 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -11.1 vs -3.5 0.3 mg (Fast Escalation) · wk 52 · n 73 · Phase 2 · secondary NCT02453711
  • -11.0 vs -3.5 0.2 mg · wk 52 · n 87 · Phase 2 · secondary NCT02453711
  • -8.8 vs -3.5 0.1 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -6.1 vs -3.5 0.05 mg · wk 52 · n 77 · Phase 2 · secondary NCT02453711
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013

Body weight, % change

orforglipron
-7.9% vs -0.6%−7.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
11 other results
  • -8.7% vs -0.6% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • -5.9% vs -0.6% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • -12.3% vs -2% 36 mg · wk 26 · n 56 · Phase 2 · primary NCT05051579
  • -8.6% vs -2% 12 mg · wk 26 · n 44 · Phase 2 · primary NCT05051579
  • -12.6% vs -2% 45 mg · wk 26 · n 57 · Phase 2 · primary NCT05051579
  • -11.2% vs -2% 24 mg · wk 26 · n 51 · Phase 2 · primary NCT05051579
  • -13.5% vs -2.3% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • -9.4% vs -2.3% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • -14.7% vs -2.3% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.5% vs -2.3% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • -9.6% vs -2.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
Semaglutide (Wegovy)
-19.5% vs -3.8%−15.7 vs placebo7.2 mg · wk 72 · n 950NCT05646706
28 other results
  • -14.2% vs -2.5% 2.4 mg · wk 68 · n 253 · Phase 3 · primary NCT05064735
  • -13.4% vs -1.9% 2.4 mg · wk 68 · n 193 · Phase 3 · primary NCT03811574
  • -14.4% vs -2.7% 2.4 mg · wk 52 · n 129 · Phase 3 · primary NCT05040971
  • -13.9% vs -2.5% 2.4 mg · wk 52 · n 246 · Phase 3 · primary NCT04788511
  • -12.2% vs -2.2% 2.4 mg · wk 44 · n 159 · Phase 3 · primary NCT06041217
  • -12.5% vs -3.6% 2.4 mg · wk 44 · n 238 · Phase 3 · primary NCT04251156
  • -9.9% vs -1.9% 1.7 mg · wk 68 · n 98 · Phase 3 · primary NCT03811574
  • -16.4% vs -2.6% wk 44 · n 100 · Phase 3 · primary NCT04998136
  • -16.4% vs -2.7% wk 44 · n 96 · Phase 3 · primary NCT04998136
  • -16.4% vs -6.4% 2.4 mg · wk 68 · n 117 · Phase 3 · primary NCT04074161
  • -9.4% vs -0.9% wk 104 · n 7474 · Phase 3 · secondary NCT03574597
  • -17.7% vs -5.4% 2.4 mg · wk 68 · n 520 · Phase 3 · secondary NCT03548987
  • -7.8% vs -6% 2.4 mg · wk 8 · n 396 · Phase 3 · secondary NCT03611582
  • -14.8% vs 2.3% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -16.4% vs -1.6% 2.4 mg · wk 68 · n 117 · Phase 3 · secondary NCT04074161
  • -15.8% vs -3.3% 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.9% vs -7.2% 2.4 mg · wk 68 · n 388 · Phase 3 · secondary NCT03552757
  • -19.5% vs -16.4% 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -5.5% vs -3.1% 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · primary NCT04969939
  • -13.8% vs -2.3% 0.4 mg · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -16.3% vs -2.3% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -11.2% vs -2.3% 0.3 mg · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.4% vs -2.3% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.6% vs -2.3% 0.2 mg · wk 52 · n 94 · Phase 2 · primary NCT02453711
  • -8.6% vs -2.3% 0.1 mg · wk 52 · n 96 · Phase 2 · primary NCT02453711
  • -6.0% vs -2.3% 0.05 mg · wk 52 · n 92 · Phase 2 · primary NCT02453711
  • -4.5% vs -0.2% wk 12 · n 43 · Phase 1 · secondary NCT04779697
  • -13.6% vs -7.4% 2.4 mg · wk 52 · n 207 · Phase 4 · secondary NCT05579249

Weight loss of 5% or more

orforglipron
58.3% vs 15%+43.3 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 61.4% vs 15% 12 mg QD · wk 72 · n 57 · Phase 3 · primary NCT05931380
  • 45.9% vs 15% 6 mg QD · wk 72 · n 61 · Phase 3 · primary NCT05931380
  • 92.0% vs 24.0% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 89.5% vs 22.9% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 72% vs 24.0% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 74.4% vs 22.9% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 90.4% vs 24.0% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 87.3% vs 22.9% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 89.5% vs 24.0% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 88.8% vs 22.9% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
Semaglutide (Wegovy)
87% vs 29.2%+57.8 vs placebo2.4 mg · wk 68 · n 253NCT05064735
1 other result
  • 72.5% vs 17.7% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189

Weight loss of 10% or more

orforglipron
38.3% vs 3.3%+35 vs placebo36 mg QD · wk 72 · n 60NCT05931380
10 other results
  • 35.1% vs 3.3% 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • 18.0% vs 3.3% 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • 74.8% vs 8.8% 36 mg · wk 36 · n 56 · Phase 2 · secondary NCT05051579
  • 71.3% vs 2.3% 36 mg · wk 26 · n 56 · Phase 2 · secondary NCT05051579
  • 46.5% vs 8.8% 12 mg · wk 36 · n 44 · Phase 2 · secondary NCT05051579
  • 39.4% vs 2.3% 12 mg · wk 26 · n 44 · Phase 2 · secondary NCT05051579
  • 69.1% vs 8.8% 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • 69.9% vs 2.3% 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • 61.9% vs 8.8% 24 mg · wk 36 · n 51 · Phase 2 · secondary NCT05051579
  • 56.6% vs 2.3% 24 mg · wk 26 · n 51 · Phase 2 · secondary NCT05051579
Semaglutide (Wegovy)
70.4% vs 9.2%+61.2 vs placebo2.4 mg · wk 68 · n 253NCT05064735
9 other results
  • 61.8% vs 8.1% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • 65.9% vs 9.5% 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • 64.6% vs 10.1% 0.4 mg · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 71.9% vs 10.1% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 57.8% vs 10.1% 0.3 mg · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 58.5% vs 10.1% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 56.0% vs 10.1% 0.2 mg · wk 52 · n 94 · Phase 2 · secondary NCT02453711
  • 36.6% vs 10.1% 0.1 mg · wk 52 · n 96 · Phase 2 · secondary NCT02453711
  • 18.9% vs 10.1% 0.05 mg · wk 52 · n 92 · Phase 2 · secondary NCT02453711

Waist circumference, change (cm)

orforglipron
-5.7 vs -0.1−5.6 vs placebo36 mg QD · wk 72 · n 60NCT05931380
12 other results
  • -5.9 vs -0.1 12 mg QD · wk 72 · n 57 · Phase 3 · secondary NCT05931380
  • -3.7 vs -0.1 6 mg QD · wk 72 · n 61 · Phase 3 · secondary NCT05931380
  • -10.6 vs -4 36 mg · wk 36 · n 52 · Phase 2 · secondary NCT05051579
  • -10.1 vs -3.6 36 mg · wk 26 · n 52 · Phase 2 · secondary NCT05051579
  • -9.6 vs -4 12 mg · wk 36 · n 43 · Phase 2 · secondary NCT05051579
  • -8 vs -3.6 12 mg · wk 26 · n 43 · Phase 2 · secondary NCT05051579
  • -13.6 vs -4 45 mg · wk 36 · n 57 · Phase 2 · secondary NCT05051579
  • -12.2 vs -3.6 45 mg · wk 26 · n 57 · Phase 2 · secondary NCT05051579
  • -11.2 vs -4 24 mg · wk 36 · n 49 · Phase 2 · secondary NCT05051579
  • -8.8 vs -3.6 24 mg · wk 26 · n 49 · Phase 2 · secondary NCT05051579
  • -5.8 n 9 · Phase 1 · secondary NCT06023095
  • -11.7 n 9 · Phase 1 · secondary NCT06023095
Semaglutide (Wegovy)
-7.5 vs -1−6.5 vs placebowk 104 · n 7373NCT03574597
35 other results
  • -14.1 vs -4.4 2.4 mg weekly · wk 68 · n 1210 · Phase 3 · secondary NCT03548935
  • -6.9 vs 3.2 2.4 mg · wk 68 · n 518 · Phase 3 · secondary NCT03548987
  • -9.7 vs -4.3 2.4 mg · wk 68 · n 387 · Phase 3 · secondary NCT03552757
  • -15.2 vs -6.1 2.4 mg · wk 68 · n 371 · Phase 3 · secondary NCT03611582
  • -18 vs -5.6 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -13.3 vs -5.9 2.4 mg · wk 68 · n 253 · Phase 3 · secondary NCT05064735
  • -12.7 vs -0.5 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -13.6 vs -2 2.4 mg · wk 68 · n 114 · Phase 3 · secondary NCT04074161
  • -11.2 vs -1.8 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -10.2 vs -1.9 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -11.6 vs -2.8 2.4 mg · wk 52 · n 129 · Phase 3 · secondary NCT05040971
  • -12 vs -2.8 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • -14.3 vs -4.5 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.1 vs -2.4 2.4 mg · wk 44 · n 159 · Phase 3 · secondary NCT06041217
  • -11.1 vs -3.8 2.4 mg · wk 44 · n 238 · Phase 3 · secondary NCT04251156
  • -15.2 vs -4.3 2.4 mg · wk 104 · n 143 · Phase 3 · secondary NCT03693430
  • -7.8 vs -1.8 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -7.6 vs -1.9 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -12 vs -3 wk 44 · n 100 · Phase 3 · secondary NCT04998136
  • -4.8 vs -2.7 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · secondary NCT04969939
  • -12.3 vs -3.5 0.4 mg · wk 52 · n 82 · Phase 2 · secondary NCT02453711
  • -14.9 vs -3.5 0.4 mg (Fast Escalation) · wk 52 · n 91 · Phase 2 · secondary NCT02453711
  • -10.9 vs -3.5 0.3 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -11.1 vs -3.5 0.3 mg (Fast Escalation) · wk 52 · n 73 · Phase 2 · secondary NCT02453711
  • -11.0 vs -3.5 0.2 mg · wk 52 · n 87 · Phase 2 · secondary NCT02453711
  • -8.8 vs -3.5 0.1 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -6.1 vs -3.5 0.05 mg · wk 52 · n 77 · Phase 2 · secondary NCT02453711
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. orforglipron: 12 of 12 rows · Semaglutide (Wegovy): 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricorforglipron
Rows use multiple source trials
Semaglutide (Wegovy)
Rows use multiple source trials
BMI
absolute change · kg
-2.63 vs -0.21 placebo kg @ 72wk36 mg QDa,b,c
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2.83 vs -0.21 placebo kg @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-1.94 vs -0.21 placebo kg @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-7.7 vs -1.5 placebo kg @ 72wk7.2 mgb,c
NCT05646706 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose
absolute change · mmol/L
-0.5 vs NA placebo mmol/La,d,b,c,e
NCT06023095 · Phase 1 · registry result, not featured evidence
show 1 more dose
-0.17 vs NA placebo mmol/L
NCT06023095 · Phase 1 · registry result, not featured evidence
-0.5 vs 0.1 placebo mmol/L @ 104wk2.4 mga,d,b,c,e
NCT03693430 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.46 vs 0.1 placebo mmol/L @ 104wk*2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.3 mg/dL as posted
HbA1c
absolute change · percentage points
-1.66% vs -0.47% placebo @ 72wkorforglipron 17.2 mgf,c
NCT05872620 · Phase 3 · sponsor-reported, not registry data
3 other source trials
-0.61% (n=57) vs 0.041% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-0.62% (n=60) vs 0.041% (n=60) placebo @ 72wk36 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-0.53% (n=61) vs 0.041% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-0.3% (n=938) vs 0% (n=167) placebo @ 72wk7.2 mgf,c
NCT05646706 · Phase 3 · registry result, not featured evidence
SBP
absolute change · mmHg
-4.36 vs -0.055 placebo mmHg @ 72wk36 mg QDa,b,c
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more doses
-3.84 vs -0.055 placebo mmHg @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-5.08 vs -0.055 placebo mmHg @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-10 vs -4 placebo mmHg @ 72wk7.2 mgb,c
NCT05646706 · Phase 3 · registry result, not featured evidence
VAT Change Cm2
absolute change · cm
-49.3 vs -7.2 placebo cm @ 72wk36 mg QDa,b,c,g
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more doses
-52.3 vs -7.2 placebo cm @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-47.5 vs -7.2 placebo cm @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-67.4 vs -13.8 placebo cm @ 68wk2.4 mga,b,c,g
NCT03811574 · Phase 3 · registry result, not featured evidence
show 1 more dose
-41.7 vs -13.8 placebo cm @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
-14.2 vs -2.4 placebo kg @ 36wk36 mga,h,b,c,i
NCT05051579 · Phase 2 · registry result, not featured evidence
show 3 more doses
-9.8 vs -2.4 placebo kg @ 36wk12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-15.4 vs -2.4 placebo kg @ 36wk45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-13.6 vs -2.4 placebo kg @ 36wk24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
-16.9 vs -2.1 placebo kg @ 104wk2.4 mgh,b,c,i
NCT03693430 · Phase 3 · registry result, not featured evidence
Weight Loss 15%
responder rate · % of participants
18.33% (n=60) vs 0% (n=60) placebo @ 72wk36 mg QDa,j,k,f,c,g
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more doses
22.81% (n=57) vs 0% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
9.84% (n=61) vs 0% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
47.8% (n=253) vs 2.5% (n=120) placebo @ 68wk2.4 mgj,k,f,c,g
Yes
NCT05064735 · Phase 3 · registry result, not featured evidence
1 other source trial
53.4% (n=131) vs 4.8% (n=62) placebo @ 68wk2.4 mg
Yes
NCT04102189 · Phase 3 · registry result, not featured evidence
Weight Loss 20%
responder rate · % of participants
8.33% (n=60) vs 0% (n=60) placebo @ 72wk36 mg QDa,j,k,f,c,g
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more doses
12.28% (n=57) vs 0% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
3.28% (n=61) vs 0% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
23.3% (n=253) vs 0% (n=120) placebo @ 68wk2.4 mgj,k,f,c,g
Yes
NCT05064735 · Phase 3 · registry result, not featured evidence
1 other source trial
37.4% (n=131) vs 3.2% (n=62) placebo @ 68wk2.4 mg
Yes
NCT04102189 · Phase 3 · registry result, not featured evidence
Dropout rate
10%36 mg QDl
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
8.8%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
11.5%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
12%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
13.2%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
8.3%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
—2.4 mg weeklym
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
5.1%2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
11%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
3.2%2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
2.9%
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
16.7%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
15.3%Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
—Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
14.4%2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
0%2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
4.6%7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
0%
NCT04998136 · Phase 3 · registry result, not featured evidence
9.2%2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
7.2%2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
2.7%2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
2%2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
1.5%2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
4.8%2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
2.6%2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
2%2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
2%1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
33.9%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
38.6%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
50%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
37.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.5%
NCT05302596 · Phase 2 · registry result, not featured evidence
0%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
2%0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
2.9%0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
6.8%0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
5.9%0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
8.7%0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
6.9%0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
10.7%0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
10.4%
NCT04779697 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
3.3%36 mg QDl
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
3.5%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
1.6%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
4%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
1.9%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
—17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
—tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
10%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
—1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
—2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
—0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
4.2%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
—2.4 mg weeklym
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
—2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
5.3%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
—
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
6.4%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
—Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
—Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
—
NCT04998136 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
—1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
1.8%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
14.3%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
5.4%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
—
NCT05302596 · Phase 2 · registry result, not featured evidence
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—
NCT04779697 · Phase 1 · registry result, not featured evidence
Serious AEs
10%36 mg QDl
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
5.3%12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
1.6%6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
0%36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
10.3%36 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%12 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
6.5%45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
3.8%24 mg
NCT05051579 · Phase 2 · registry result, not featured evidence
0%17.2 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.6%36 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%12 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.5%6 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%24 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%14.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%9 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0.5%5.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%3 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%2.5 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%1 mg capsule QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%0.8 mg tablet QD
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 1)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 2)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 3)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 4)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 5)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 6)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 7)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 8)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 9)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 10)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 12)
NCT06440980 · Phase 1 · registry result, not featured evidence
2%tablet QD (dose level 13)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 14)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 15)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 16)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 18)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 11)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%tablet QD (dose level 17)
NCT06440980 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 1)
NCT06023095 · Phase 1 · registry result, not featured evidence
0%LY3502970 (Cohort 2)
NCT06023095 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
5.3%12 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%6 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg + 0.2 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 0.25 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%36 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%24 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%20 mg + 20 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%3 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%1 mg + 1000 mg
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
0%1 mg QD
NCT06186622 · Phase 1 · registry result, not featured evidence
0%36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
2.2%36 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%36 mg DF capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%36 mg EPB capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%60 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%45 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%37.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%35 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
2.2%20 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%16 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%10 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%8 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%2.5 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%2 mg capsule
NCT05841238 · Phase 1 · registry result, not featured evidence
0%0.8 mg tablet
NCT05841238 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 1
NCT05313802 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 2
NCT05313802 · Phase 1 · registry result, not featured evidence
0%LY3502970 Cohort 3
NCT05313802 · Phase 1 · registry result, not featured evidence
9.8%2.4 mg weeklym
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
—2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
7.7%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
9.9%2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
33.4%
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
9.1%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
4.2%Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
0%Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
1.2%2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
8.1%2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
7.3%7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
12.9%
NCT04998136 · Phase 3 · registry result, not featured evidence
10%2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
8.7%2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
13.3%2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
5.6%2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
11.3%2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
7.9%2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
7.9%2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
5%2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
7%1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.7%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.5%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
14.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
0%
NCT05302596 · Phase 2 · registry result, not featured evidence
12.5%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
4.3%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
12.7%0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
6.8%0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
5.8%0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
5.9%0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
4.9%0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
7.8%0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
12.6%0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
2.1%
NCT04779697 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
36 mg QDl
nausea 33.3% (placebo 0%)
constipation 31.7% (placebo 8.3%)
nasopharyngitis 20% (placebo 35%)
NCT05931380 · Phase 3 · registry result, not featured evidence
show 97 more results
12 mg QD
nasopharyngitis 42.1% (placebo 35%)
constipation 28.1% (placebo 8.3%)
nausea 15.8% (placebo 0%)
NCT05931380 · Phase 3 · registry result, not featured evidence
6 mg QD
constipation 36.1% (placebo 8.3%)
nasopharyngitis 26.2% (placebo 35%)
diarrhoea 14.8% (placebo 3.3%)
NCT05931380 · Phase 3 · registry result, not featured evidence
36 mg
nausea 41.4% (placebo 10%)
constipation 27.6% (placebo 6%)
vomiting 27.6% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
36 mg
nausea 48.3% (placebo 10%)
constipation 24.1% (placebo 6%)
covid-19 24.1% (placebo 18%)
NCT05051579 · Phase 2 · registry result, not featured evidence
12 mg
nausea 50% (placebo 10%)
vomiting 26% (placebo 6%)
constipation 24% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
45 mg
nausea 41.9% (placebo 10%)
vomiting 29% (placebo 6%)
constipation 19.4% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
45 mg
nausea 36.7% (placebo 10%)
diarrhoea 33.3% (placebo 10%)
vomiting 26.7% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
24 mg
nausea 58.5% (placebo 10%)
diarrhoea 35.8% (placebo 10%)
constipation 32.1% (placebo 6%)
NCT05051579 · Phase 2 · registry result, not featured evidence
17.2 mg tablet QD
vomiting 5.7%
headache 3.4%
nausea 3.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
36 mg capsule QD
headache 6.7%
constipation 4.4%
dizziness 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
36 mg capsule QD
headache 15.9%
vomiting 10.8%
diarrhoea 6.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
12 mg capsule QD
constipation 6%
nausea 6%
headache 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
12 mg capsule QD
constipation 21%
headache 19.4%
nausea 17.2%
NCT06440980 · Phase 1 · registry result, not featured evidence
6 mg capsule QD
headache 8.7%
dyspepsia 4.3%
vomiting 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
6 mg capsule QD
headache 12.3%
nausea 9.4%
dyspepsia 7.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
24 mg capsule QD
headache 10%
vomiting 6%
abdominal pain 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
24 mg capsule QD
nausea 17.1%
diarrhoea 12.7%
constipation 10.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
14.5 mg tablet QD
headache 8.3%
nausea 8.3%
diarrhoea 6.7%
NCT06440980 · Phase 1 · registry result, not featured evidence
9 mg tablet QD
headache 9.7%
constipation 9.1%
vomiting 8.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
5.5 mg tablet QD
headache 8.4%
nausea 8.4%
constipation 4.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
3 mg capsule QD
nausea 4.3%
decreased appetite 2.1%
diarrhoea 2.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
3 mg capsule QD
headache 17.6%
nausea 13.8%
constipation 9.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
2.5 mg tablet QD
headache 8.1%
constipation 6.2%
nausea 6.2%
NCT06440980 · Phase 1 · registry result, not featured evidence
1 mg capsule QD
constipation 7.7%
decreased appetite 1.9%
eructation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
1 mg capsule QD
constipation 27%
headache 15.8%
nausea 6%
NCT06440980 · Phase 1 · registry result, not featured evidence
0.8 mg tablet QD
constipation 8.9%
headache 8.9%
dyspepsia 4.7%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 1)
constipation 9.6%
diarrhoea 1.9%
eructation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 2)
abdominal pain 3.8%
diarrhoea 3.8%
constipation 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 3)
constipation 13.5%
abdominal distension 1.9%
dizziness 1.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 4)
nausea 7.8%
vomiting 7.8%
constipation 5.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 5)
nausea 8.3%
dyspepsia 6.3%
headache 6.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 6)
diarrhoea 5.9%
abdominal pain 3.9%
constipation 3.9%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 7)
nausea 6.5%
dyspepsia 4.3%
headache 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 8)
dyspepsia 6.4%
headache 4.3%
nausea 4.3%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 9)
nausea 10.9%
abdominal distension 6.5%
abdominal pain 6.5%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 10)
constipation 8%
diarrhoea 6%
dyspepsia 6%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 12)
nausea 8%
headache 6%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 13)
constipation 8.2%
abdominal pain 4.1%
diarrhoea 4.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 14)
dizziness 12.2%
headache 6.1%
abdominal pain 4.1%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 15)
nausea 8%
constipation 4%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 16)
heart rate increased 8.9%
constipation 4.4%
headache 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 18)
constipation 6.7%
diarrhoea 6.7%
nausea 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 11)
dyspepsia 6%
constipation 4%
diarrhoea 4%
NCT06440980 · Phase 1 · registry result, not featured evidence
tablet QD (dose level 17)
nausea 13.3%
headache 6.7%
diarrhoea 4.4%
NCT06440980 · Phase 1 · registry result, not featured evidence
decreased appetite 70% (placebo 50%)
diarrhoea 60% (placebo 25%)
eructation 40% (placebo 0%)
NCT06023095 · Phase 1 · registry result, not featured evidence
nausea 80% (placebo 0%)
decreased appetite 70% (placebo 50%)
diarrhoea 70% (placebo 25%)
NCT06023095 · Phase 1 · registry result, not featured evidence
36 mg
constipation 4.5%
diarrhoea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain upper 4.5%
dizziness 4.5%
vomiting 4.5%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
back pain 4.5%
diarrhoea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
constipation 23.1%
nausea 11.5%
abdominal pain 7.7%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
constipation 22.2%
alopecia 5.6%
diarrhoea 5.6%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg QD
anxiety 6.3%
constipation 6.3%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence
12 mg QD
alanine aminotransferase increased 3.8%
aspartate aminotransferase increased 3.8%
fatigue 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
12 mg QD
back pain 5.3%
constipation 5.3%
cough 5.3%
NCT06186622 · Phase 1 · registry result, not featured evidence
6 mg QD
dyspepsia 7.7%
nausea 7.7%
diarrhoea 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
6 mg QD
fatigue 15.8%
eructation 10.5%
headache 10.5%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg + 0.2 mg
dizziness 4.8%
headache 4.8%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 0.25 mg
nausea 9.1%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
decreased appetite 4.5%
headache 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 1000 mg
headache 4.5%
nausea 4.5%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 0.25 mg
constipation 6.3%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
abdominal pain upper 6.3%
abdominal pain 0%
alanine aminotransferase increased 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
36 mg + 20 mg
dysmenorrhoea 6.3%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
24 mg QD
abdominal pain 3.8%
diarrhoea 3.8%
headache 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
24 mg QD
constipation 5.6%
diarrhoea 5.6%
eructation 5.6%
NCT06186622 · Phase 1 · registry result, not featured evidence
20 mg + 20 mg
alanine aminotransferase increased 9.1%
aspartate aminotransferase increased 9.1%
abdominal pain 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
20 mg + 20 mg
alanine aminotransferase increased 12.5%
aspartate aminotransferase increased 12.5%
headache 6.3%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
3 mg QD
diarrhoea 3.8%
fatigue 3.8%
nausea 3.8%
NCT06186622 · Phase 1 · registry result, not featured evidence
3 mg QD
abdominal pain 10%
nausea 10%
alanine aminotransferase increased 5%
NCT06186622 · Phase 1 · registry result, not featured evidence
1 mg QD
medication error 7.4%
dysmenorrhoea 3.7%
fatigue 3.7%
NCT06186622 · Phase 1 · registry result, not featured evidence
1 mg + 1000 mg
headache 3.7%
abdominal pain 0%
abdominal pain upper 0%
NCT06186622 · Phase 1 · registry result, not featured evidence · combination
1 mg QD
eructation 15%
decreased appetite 10%
headache 10%
NCT06186622 · Phase 1 · registry result, not featured evidence
36 mg capsule
nausea 9.5%
abdominal pain 4.8%
constipation 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg capsule
diarrhoea 4.4%
abdominal pain 2.2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg DF capsule
constipation 8.3%
diarrhoea 8.3%
nausea 8.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
36 mg EPB capsule
nausea 41.7%
headache 16.7%
diarrhoea 8.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
60 mg tablet
vomiting 14.3%
constipation 4.8%
dyspepsia 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
45 mg tablet
abdominal distension 9.5%
nausea 9.5%
vomiting 4.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
37.5 mg tablet
headache 19%
nausea 19%
constipation 9.5%
NCT05841238 · Phase 1 · registry result, not featured evidence
37.5 mg tablet
nausea 14.6%
headache 12.2%
vomiting 12.2%
NCT05841238 · Phase 1 · registry result, not featured evidence
35 mg tablet
dyspepsia 14.3%
flatulence 14.3%
nausea 14.3%
NCT05841238 · Phase 1 · registry result, not featured evidence
35 mg tablet
intertrigo 14.3%
abdominal distension 0%
abdominal pain 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
20 mg tablet
dyspepsia 4.3%
abdominal pain 2.2%
diarrhoea 2.2%
NCT05841238 · Phase 1 · registry result, not featured evidence
16 mg capsule
diarrhoea 6.5%
vomiting 2.2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
10 mg tablet
constipation 12.2%
nausea 4.1%
dyspepsia 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
8 mg capsule
dyspepsia 10.2%
decreased appetite 6.1%
diarrhoea 6.1%
NCT05841238 · Phase 1 · registry result, not featured evidence
5 mg tablet
headache 12%
dyspepsia 4%
abdominal pain 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
2.5 mg tablet
headache 4%
decreased appetite 2%
gastrooesophageal reflux disease 2%
NCT05841238 · Phase 1 · registry result, not featured evidence
2 mg capsule
constipation 10%
diarrhoea 2%
abdominal distension 0%
NCT05841238 · Phase 1 · registry result, not featured evidence
0.8 mg tablet
constipation 3.8%
headache 3.8%
nausea 3.8%
NCT05841238 · Phase 1 · registry result, not featured evidence
constipation 37.5%
headache 33.3%
weight decreased 25%
NCT05313802 · Phase 1 · registry result, not featured evidence
dyspepsia 41.7%
constipation 33.3%
weight decreased 29.2%
NCT05313802 · Phase 1 · registry result, not featured evidence
constipation 25%
dyspepsia 25%
headache 16.7%
NCT05313802 · Phase 1 · registry result, not featured evidence
2.4 mg weeklym
nausea 44.1% (placebo 17.4%)
diarrhoea 31.5% (placebo 15.9%)
vomiting 24.6% (placebo 6.6%)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
2.4 mg
diarrhoea 14.4% (placebo 7.1%)
nausea 14% (placebo 4.9%)
constipation 11.6% (placebo 6%)
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2.4 mg
nausea 33.5% (placebo 9.2%)
diarrhoea 21.3% (placebo 11.9%)
vomiting 21.3% (placebo 2.7%)
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
covid-19 20.3% (placebo 20.3%)
nausea 18.1% (placebo 3.8%)
diarrhoea 10.6% (placebo 4%)
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
2.4 mg
nausea 58.2% (placebo 22.1%)
constipation 36.9% (placebo 24.5%)
diarrhoea 36.1% (placebo 22.1%)
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
nausea 73.6% (placebo 25%)
constipation 52.8% (placebo 16.7%)
diarrhea 37.5% (placebo 22.9%)
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
diarrhea 20% (placebo 22.9%)
constipation 10% (placebo 16.7%)
eructation 10% (placebo 6.3%)
NCT05548647 · Phase 4 · registry result, not featured evidence
2.4 mg
decreased appetite 19.3% (placebo 2.5%)
diarrhoea 18.6% (placebo 7.4%)
nausea 18% (placebo 2.5%)
NCT06041217 · Phase 3 · registry result, not featured evidence
7.2 mg
nausea 43.7% (placebo 13.4%)
diarrhoea 27.3% (placebo 12.9%)
vomiting 24.8% (placebo 7%)
NCT05646706 · Phase 3 · registry result, not featured evidence
nausea 37.6% (placebo 14.3%)
diarrhoea 27.7% (placebo 6.1%)
constipation 21.8% (placebo 16.3%)
NCT04998136 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 21.9% (placebo 8.9%)
covid-19 18.6% (placebo 22.2%)
constipation 11.9% (placebo 5.2%)
NCT05064735 · Phase 3 · registry result, not featured evidence
2.4 mg
covid-19 34.8% (placebo 30.4%)
nausea 29% (placebo 4.3%)
constipation 18.1% (placebo 0%)
NCT05040971 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 17.1% (placebo 2.6%)
covid-19 13.7% (placebo 15.4%)
diarrhoea 9.1% (placebo 3.8%)
NCT04788511 · Phase 3 · registry result, not featured evidence
2.4 mg
diarrhoea 26.1% (placebo 10.3%)
nausea 24.1% (placebo 7.1%)
upper respiratory tract infection 20.5% (placebo 20.6%)
NCT04251156 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 42.1% (placebo 17.9%)
vomiting 36.1% (placebo 10.4%)
diarrhoea 21.8% (placebo 19.4%)
NCT04102189 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 61.1% (placebo 22.4%)
constipation 38.9% (placebo 23.5%)
diarrhoea 27.8% (placebo 25.9%)
NCT04074161 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 53.3% (placebo 21.7%)
diarrhoea 34.9% (placebo 23.7%)
constipation 30.9% (placebo 11.2%)
NCT03693430 · Phase 3 · registry result, not featured evidence
2.4 mg
nasopharyngitis 26.6% (placebo 17.8%)
constipation 26.1% (placebo 3%)
nausea 17.6% (placebo 4%)
NCT03811574 · Phase 3 · registry result, not featured evidence
1.7 mg
nasopharyngitis 24% (placebo 17.8%)
diarrhoea 22% (placebo 5.9%)
constipation 19% (placebo 3%)
NCT03811574 · Phase 3 · registry result, not featured evidence
30 mg/kg + 1.0 mg
muscle spasms 64.3%
acne 55.4%
diarrhoea 44.6%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
30 mg/kg + 2.4 mg
muscle spasms 63.6%
acne 52.7%
diarrhoea 49.1%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10 mg/kg + 1.0 mg
muscle spasms 57.1%
diarrhoea 48.2%
acne 42.9%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10 mg/kg + 2.4 mg
muscle spasms 65.5%
nausea 61.8%
diarrhoea 52.7%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
gastrointestinal side effects: constipation 57.1%
gi side effects: nausea 28.6%
gi side effects: vomiting 14.3%
NCT05302596 · Phase 2 · registry result, not featured evidence
2.0 mg + 2.4 mg
decreased appetite 87.5% (placebo 75%)
nausea 87.5% (placebo 12.5%)
vomiting 75% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
2.0 mg + 2.4 mg
nausea 62.5% (placebo 12.5%)
constipation 50% (placebo 0%)
vomiting 37.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
1.0 mg + 2.4 mg
decreased appetite 87.5% (placebo 75%)
nausea 50% (placebo 12.5%)
abdominal pain 37.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
1.0 mg + 2.4 mg
nausea 44.7% (placebo 12.5%)
vomiting 31.9% (placebo 0%)
constipation 25.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0.4 mg
nausea 48% (placebo 17.6%)
diarrhoea 37.3% (placebo 11.8%)
constipation 23.5% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.4 mg (Fast Escalation)
nausea 48.5% (placebo 17.6%)
constipation 28.2% (placebo 4.4%)
diarrhoea 27.2% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.3 mg
nausea 41.7% (placebo 17.6%)
diarrhoea 26.2% (placebo 11.8%)
constipation 17.5% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.3 mg (Fast Escalation)
nausea 53.9% (placebo 17.6%)
diarrhoea 27.5% (placebo 11.8%)
vomiting 20.6% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.2 mg
nausea 43.7% (placebo 17.6%)
diarrhoea 34% (placebo 11.8%)
constipation 25.2% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.1 mg
nausea 41.2% (placebo 17.6%)
diarrhoea 24.5% (placebo 11.8%)
nasopharyngitis 22.5% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.05 mg
nausea 31.1% (placebo 17.6%)
diarrhoea 19.4% (placebo 11.8%)
nasopharyngitis 15.5% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
nausea 58.3% (placebo 20.8%)
abdominal pain 31.3% (placebo 20.8%)
diarrhea 29.2% (placebo 10.4%)
NCT04779697 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 1 versus Phase 3.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation context differs: registered conditions differ.
  7. gAssessment timepoints differ: 72 weeks versus 68 weeks.
  8. hTrial phases differ: Phase 2 versus Phase 3.
  9. iAssessment timepoints differ: 36 weeks versus 104 weeks.
  10. jThe reported result categories differ.
  11. kOne study enrolled healthy volunteers and the other enrolled patients.
  12. lPopulation comparability has not been reviewed for these studies.
  13. mPopulation comparability has not been reviewed for 30 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

orforglipron

HbA1c Less Than 6 5 78.57% (n=14) vs 0% (n=14) placebo @ 72wk36 mg QD
responder rate · % of participants
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
45.45% (n=11) vs 0% (n=14) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
31.25% (n=16) vs 0% (n=14) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Non-HDL-C -10.75% (n=60) vs 0.05% (n=60) placebo @ 72wk36 mg QD
percent change · % of baseline
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-10.2% (n=57) vs 0.05% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-6.91% (n=61) vs 0.05% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
HDL-C 5.17% (n=60) vs 7.37% (n=60) placebo @ 72wk36 mg QD
percent change · % of baseline
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
8.62% (n=57) vs 7.37% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
5.75% (n=61) vs 7.37% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
TG -15.64% (n=60) vs -9.61% (n=60) placebo @ 72wk36 mg QD
percent change · % of baseline
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-24.85% (n=57) vs -9.61% (n=60) placebo @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-16.85% (n=61) vs -9.61% (n=60) placebo @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
Fasting Glucose Change mg/dL -17.79 vs -0.31 placebo mg @ 72wk36 mg QD
absolute change · mg
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
-15.5 vs -0.31 placebo mg @ 72wk12 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
-13.98 vs -0.31 placebo mg @ 72wk6 mg QD
NCT05931380 · Phase 3 · registry result, not featured evidence
IWQOL-Lite-CT Physical Function 2.51 vs -0.43 placebo score @ 72wk36 mg QD
absolute change · score
Physical Function Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
3.08 vs -0.43 placebo score @ 72wk12 mg QD
Physical Function Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
3.71 vs -0.43 placebo score @ 72wk6 mg QD
Physical Function Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
IWQoL-Lite CT Psychosocial 4.02 vs 1.74 placebo score @ 72wk36 mg QD
absolute change · score
Psychosocial Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
show 2 more results
5.41 vs 1.74 placebo score @ 72wk12 mg QD
Psychosocial Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
3.47 vs 1.74 placebo score @ 72wk6 mg QD
Psychosocial Composite Scores
NCT05931380 · Phase 3 · registry result, not featured evidence
Weight -4.2 kg @ 4.14wk
absolute change · kg
No placebo or comparator arm
NCT05313802 · Phase 1 · registry result, not featured evidence
show 2 more results
-5.5 kg @ 4.14wk
NCT05313802 · Phase 1 · registry result, not featured evidence
-3.6 kg @ 4.14wk
NCT05313802 · Phase 1 · registry result, not featured evidence

Semaglutide (Wegovy)

Weight -15.6% (n=1306) vs -2.8% (n=655) placebo @ 68wk2.4 mg weekly
percent change · % of baseline
In-trial observation period
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 3 more results
-9.9% (n=404) vs -3.3% (n=403) placebo @ 68wk2.4 mg
In-trial observation period
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-16.5% (n=407) vs -5.8% (n=204) placebo @ 68wk2.4 mg
In-trial observation period
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-15.9% (n=144) vs -1.9% (n=128) placebo @ 104wk2.4 mg
In-trial observation period
NCT03693430 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 80.2% (n=1306) vs 27.8% (n=655) placebo @ 68wk2.4 mg weekly
event count · % of participants
In-trial observation period · Yes
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 1047 Participants as posted
show 3 more results
66.1% (n=404) vs 26.6% (n=403) placebo @ 68wk*2.4 mg
In-trial observation period · Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 267 Participants as posted
79.4% (n=407) vs 44.1% (n=204) placebo @ 68wk*2.4 mg
In-trial observation period · Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 323 Participants as posted
77.1% (n=144) vs 34.4% (n=128) placebo @ 104wk*2.4 mg
In-trial observation period · Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 111 Participants as posted
Weight Loss 10% 69.1% (n=1212) vs 12% (n=577) placebo @ 68wk2.4 mg weekly
event count · % of participants
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 838 Participants as posted
show 14 more results
79% (n=520) vs 20.4% (n=250) placebo @ 68wk*2.4 mg
Yes
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 411 Participants as posted
45.6% (n=388) vs 8.2% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 177 Participants as posted
75.3% (n=373) vs 27% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 281 Participants as posted
63.8% (n=207) vs 34.5% (n=177) Other Anti-obesity Medications (AOMs) @ 52wk*2.4 mg
Yes
NCT05579249 · Phase 4 · registry result, not featured evidence · converted to % from 132 Participants as posted
60.4% (n=159) vs 11.5% (n=78) placebo @ 44wk*2.4 mg
Yes
NCT06041217 · Phase 3 · registry result, not featured evidence · converted to % from 96 Participants as posted
73.6% (n=129) vs 7.6% (n=66) placebo @ 52wk*2.4 mg
Yes
NCT05040971 · Phase 3 · registry result, not featured evidence · converted to % from 95 Participants as posted
63.4% (n=238) vs 10.3% (n=116) placebo @ 44wk*2.4 mg
Yes
NCT04251156 · Phase 3 · registry result, not featured evidence · converted to % from 151 Participants as posted
70.9% (n=117) vs 15.4% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
61.8% (n=144) vs 13.3% (n=128) placebo @ 104wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 89 Participants as posted
68.5% (n=149) vs 13.2% (n=129) placebo @ 52wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 102 Participants as posted
60.6% (n=193) vs 5% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 117 Participants as posted
41.8% (n=98) vs 5% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
82.4% (n=950) vs 20.5% (n=171) placebo @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 783 Participants as posted
78% (n=100) vs 10.4% (n=48) placebo @ 44wk*
Yes
NCT04998136 · Phase 3 · registry result, not featured evidence · converted to % from 78 Participants as posted
Weight Loss 15% 50.5% (n=1212) vs 4.9% (n=577) placebo @ 68wk2.4 mg weekly
event count · % of participants
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 612 Participants as posted
show 13 more results
63.7% (n=520) vs 9.2% (n=250) placebo @ 68wk*2.4 mg
Yes
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 331 Participants as posted
25.8% (n=388) vs 3.2% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 100 Participants as posted
55.8% (n=373) vs 13.2% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 208 Participants as posted
44.9% (n=207) vs 14.1% (n=177) Other Anti-obesity Medications (AOMs) @ 52wk*2.4 mg
Yes
NCT05579249 · Phase 4 · registry result, not featured evidence · converted to % from 93 Participants as posted
48.1% (n=129) vs 1.5% (n=66) placebo @ 52wk*2.4 mg
Yes
NCT05040971 · Phase 3 · registry result, not featured evidence · converted to % from 62 Participants as posted
34.5% (n=238) vs 6% (n=116) placebo @ 44wk*2.4 mg
Yes
NCT04251156 · Phase 3 · registry result, not featured evidence · converted to % from 82 Participants as posted
55.6% (n=117) vs 6.4% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 65 Participants as posted
52.1% (n=144) vs 7% (n=128) placebo @ 104wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 75 Participants as posted
52.3% (n=149) vs 5.4% (n=129) placebo @ 52wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 78 Participants as posted
40.9% (n=193) vs 3% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 79 Participants as posted
24.5% (n=98) vs 3% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
66.5% (n=950) vs 7.6% (n=171) placebo @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 632 Participants as posted
53% (n=100) vs 4.2% (n=48) placebo @ 44wk*
Yes
NCT04998136 · Phase 3 · registry result, not featured evidence · converted to % from 53 Participants as posted
Weight Loss 20% 32% (n=1212) vs 1.7% (n=577) placebo @ 68wk2.4 mg weekly
event count · % of participants
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 388 Participants as posted
show 13 more results
13.1% (n=388) vs 1.6% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 51 Participants as posted
35.7% (n=373) vs 3.7% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 133 Participants as posted
23.7% (n=207) vs 4.5% (n=177) Other Anti-obesity Medications (AOMs) @ 52wk*2.4 mg
Yes
NCT05579249 · Phase 4 · registry result, not featured evidence · converted to % from 49 Participants as posted
24.8% (n=129) vs 0% (n=66) placebo @ 52wk*2.4 mg
Yes
NCT05040971 · Phase 3 · registry result, not featured evidence · converted to % from 32 Participants as posted
14.3% (n=238) vs 1.7% (n=116) placebo @ 44wk*2.4 mg
Yes
NCT04251156 · Phase 3 · registry result, not featured evidence · converted to % from 34 Participants as posted
38.5% (n=117) vs 2.6% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 45 Participants as posted
36.1% (n=144) vs 2.3% (n=128) placebo @ 104wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 52 Participants as posted
34.9% (n=149) vs 2.3% (n=129) placebo @ 52wk*2.4 mg
Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 52 Participants as posted
19.7% (n=193) vs 2% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 38 Participants as posted
11.2% (n=98) vs 2% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
47.7% (n=950) vs 2.9% (n=171) placebo @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 453 Participants as posted
47.7% (n=950) vs 33.3% (n=189) Semaglutide @ 72wk*7.2 mg
Yes
NCT05646706 · Phase 3 · registry result, not featured evidence · converted to % from 453 Participants as posted
30% (n=100) vs 0% (n=48) placebo @ 44wk*
Yes
NCT04998136 · Phase 3 · registry result, not featured evidence · converted to % from 30 Participants as posted
SF-36 Physical Functioning 2.3 vs 0.4 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in physical functioning score (SF-36)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 2 more results
1 vs -1.2 placebo score @ 68wk2.4 mg
Change in physical functioning score (SF-36)
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2.5 vs 1.7 placebo score @ 68wk2.4 mg
Change in physical functioning score (SF-36)
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 - Role Physical 1.1 vs -0.2 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (role-physical score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Bodily Pain 0.5 vs -1.3 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (bodily pain score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 General Health 2 vs -0.6 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (general health score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Vitality 0.7 vs -1.3 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (vitality score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Social Functioning -0.3 vs -1.4 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (social functioning score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 - Role Emotional -0.9 vs -1.5 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (role-emotional score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3

+ 134 further endpoints in the CSV export.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07223593 (registry estimate)

No aligned efficacy figure on record for this race.

Semaglutide (Wegovy)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT03574597 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 17,604 participants and a hard cardiovascular event primary endpoint. The primary endpoint was met: 569 participants receiving semaglutide versus 701 receiving placebo experienced a qualifying event, with a hazard ratio of 0.80 (95% CI 0.72–0.89; p<0.0001).

Reported efficacy

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)

Result source: NCT03574597

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointorforglipronSemaglutide (Wegovy)
LDL-C, % change—Trial running · NCT07241390—Not reported
Non-HDL-C, % change—Trial running · NCT07241390—Not reported
ApoB, % change—Trial running · NCT07241390—Not reported
Lp(a), % change—Trial running · NCT07241390—Not reported
3-point MACE (% with event)—Trial running · NCT07241390—Not reported

LDL-C, % change

orforglipron
—Trial running · NCT07241390
Semaglutide (Wegovy)
—Not reported

Non-HDL-C, % change

orforglipron
—Trial running · NCT07241390
Semaglutide (Wegovy)
—Not reported

ApoB, % change

orforglipron
—Trial running · NCT07241390
Semaglutide (Wegovy)
—Not reported

Lp(a), % change

orforglipron
—Trial running · NCT07241390
Semaglutide (Wegovy)
—Not reported

3-point MACE (% with event)

orforglipron
—Trial running · NCT07241390
Semaglutide (Wegovy)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

orforglipron: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Semaglutide (Wegovy)
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 NCT03574597 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Semaglutide (Wegovy)'s landscape